[长期生物治疗对中度至严重斑块牛皮的代谢生物化学参数的影响]
Xiangxian Liu1,2, Yi Lin1,2, Jinzhu Guo1
1Department of Dermatology, Peking University Third Hospital, Beijing 100191, China.
概括
长期治疗牛皮的生物治疗可能会增加IL-17抑制剂的尿酸水平,而IL-17,IL-23和IL-12/23抑制剂可能会降低患者的LDL-C水平.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 代谢医学是一种代谢医学.
背景情况:
- 中度至重度的斑块性牛皮是一种慢性炎症状况.
- 针对特定细胞因子的生物疗法是有效的治疗方法.
- 这些生物制剂的长期代谢效应需要进一步研究.
研究的目的:
- 评估长期生物治疗对中度至重度斑块牛皮患者代谢生物化学参数的影响.
- 为了比较不同生物类 (IL-17,IL-23,IL-12/23,TNF-α抑制剂) 对代谢标记物的影响.
主要方法:
- 分析了174名患有中度至重度斑块性牛皮的成年患者队列,这些患者至少接受了24周的生物治疗.
- 根据使用的生物制剂,患者被分为三组:IL-17抑制剂,IL-23/IL-12/23抑制剂和TNF-α抑制剂.
- 代谢生化参数,包括脂质,葡萄糖,肝酶和尿酸,在长期生物治疗前后进行了比较.
主要成果:
- 长期使用IL-17抑制剂与LDL-C显著降低和尿酸水平显著增加有关,特别是在正常尿酸基线的患者中.
- IL-23/IL-12/23抑制剂也显示了LDL-C水平的显著降低.
- 在治疗组中没有观察到体重,BMI,葡萄糖,肝酶或HDL-C的显著变化. TNF-α 抑制剂没有显著改变任何测量的代谢参数.
结论:
- 对斑块性牛皮的长期IL-17抑制剂治疗可能导致高尿血.
- IL-17,IL-23和IL-12/23抑制剂在降低LDL-C水平方面显示出潜在的益处.
- 对于长期接受IL-17抑制剂治疗的患者,建议监测尿酸水平.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
01:20Measurement of Bioavailability: Pharmacodynamic Methods
230
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
230
01:29Inflammatory Bowel Disease IV: Pharmacological Management
496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
496
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
245
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
245